New Partnership to Develop Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
Search
Partnership to Develop Urea Cycle Disorders Therapy
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Partnering in Central Nervous System Diseases
We are looking for new early-science collaborations. Join our expanding community of innovation partners in central nervous system diseases.
Innovation Prize Winners
Find out more about the winners of our Innovation Prize in Boston, New York and San Diego in the USA; Tokyo Japan and Vienna, Austria
Outlook for Partnering in Animal Health 2024
Megan Grether, Head of Business Development & Licensing for Animal Health, shares her perspectives on the year ahead for partnering in Animal Health.
Our Venture Fund on the search for groundbreaking trends
The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
STOP Rabies: moving towards elimination
Rabies still kills thousands of people every year. However, rabies is 100 percent vaccine preventable. We contribute to eliminating the disease.
The Boehringer Ingelheim Veterinary Scholars Program
The aim of the Boehringer Ingelheim Veterinary Scholars Program is to expose students to biomedical research
Phase 3 studies survodutide obesity and overweight
Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Implementing the generalized pustular psoriasis (GPP) Charter
Read more about the projects are implementing the generalized pustular psoriasis (GPP) Charter
Global Top Employer 2023
Global Top Employer 2023
Our evolved employer value proposition
Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
empulse-trial-benefit-acute-heart-failure
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
Focus on Alliance Management
Stefan Walke, Global Head of Alliance Management, shares his perspectives on Alliance Management and its contribution to the development of successful long-term partnerships.
Health Equity: No distance is too far
India is hosting the G20 summit. The leading theme of the G20 summit emphasizes health equity and sustainability as part of the agenda. How we provide access to healthcare for rural areas in India.
Reimagining digital healthcare worldwide
How does our digital lab BI X innovate in Ingelheim and Shanghai? Read about success stories based on different ideation processes
Phase II clinical trial weight loss results
Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)
Collaboration with Mary Tyler Moore Vision Initiative
Boehringer Ingelheim joins forces with Mary Tyler Moore Vision Initiative to combat vision loss from diabetes
2018 Animal Welfare Medals
2018 Animal Welfare Medals: Boehringer Ingelheim recognizes outstanding research in cattle, equine, swine, as well as small animals and pet categories
1885-1948: Innovative beginnings
The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products
The Research Process
The Research Process
COPD Patient Survey Infographic
Microbial Manufacturing Platform for Non-Platform Proteins
Microbial Manufacturing Platform for Non-Platform Proteins
Early careers
At Boehringer Ingelheim, we know how important it is to lay the right foundations in your career and build on them with care and support.
Listen to the sounds disrupting farms worldwide
A pioneer in Precision Livestock Farming, Prof. Daniel Berckmans reveals how online monitoring technology is bringing healthier pigs closer to farmers and consumers